Two Healthcare stocks – RadNet Inc (NASDAQ: RDNT) and Tekmira Pharmaceuticals Corp (TSX: TKM) lead the top small cap stock gainers for various sectors on both sides the border, including one that saw its share price soar of 47%
Top U.S. Gainer
|
Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
RadNet Inc |
NASDAQ |
RDNT |
289.3 |
6.92 |
1,828,235 |
20.8% |
33.9% |
7.67 |
1.50 |
RadNet Inc (NASDAQ: RDNT), engaged in providing freestanding, fixed-site outpatient diagnostic imaging services in the U.S., was the top performer in the U.S. healthcare sector after climbing 20.8% yesterday while recording huge trading volumes of 5.8 million shares on strong second quarter results and increased guidance. The stock closed at $6.92 breaking the key technical resistance levels of 30-day and 50-day DMAs of $5.90 & $3.34 respectively. During the past 5-trading sessions, the stock gained 33.8% with daily average trading volumes of 883,971 shares, while the stock accumulated over 15% in the past one month with daily average trading volumes of 690,409 shares. The stock is up 314% year-to-date. For the second quarter of 2014, RDNT reported that its net income increased to $5.14 million or $0.12 per share from $2.69 million or $0.07 per share in the same quarter last year. The company revised upward its 2014 revenue guidance to a range of $705 million $735 million from the prior estimate of $700 million – $730 million.
1-Year Price Chart
Top Canadian Gainer
| Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
Tekmira Pharmaceuticals |
TSX |
TKM |
507.8 |
23.00 |
1,374,703 |
47.3% |
66.2% |
34.66 |
5.26 |
Shares of Tekmira Pharmaceuticals Corp (TSX: TKM), a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners, skyrocketed 47% Friday after U.S. FDA verbally confirmed it would use the company’s experimental Ebola treatment in people infected with the virus. The stock was the top gainer in the Canadian healthcare sector in the last trading session and closed at C$23.00 while recording huge volumes of 1.4 million shares. During the past 5-trading sessions, the stock rallied 66.2% with daily average trading volumes of 482,386 shares, while the stock rallied over 107% during the past one month with daily average trading volumes of 162,052 shares. The stock is up 172% year-to-date.
1-Year Price Chart
